In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RespireRx Pharmaceuticals Inc.

http://www.respirerx.com

Latest From RespireRx Pharmaceuticals Inc.

UK As New Global Base, Serum Institute Mulls Acquisition Or Greenfield Unit

After setting up a sales base in the UK, Serum Institute could consider an acquisition in Europe or investment in an Oxford facility as it ties up production for its multiple COVID-19 vaccines. Is Wockhardt’s Wrexham facility an option?

Commercial Coronavirus COVID-19

WHO Chief Scientist Warns Of 'Pandemic Within A Pandemic', Calls For New R&D Models

A high profile panel including the WHO's chief scientist and ministers of Norway and South Africa discussed critical dimensions pertaining to coronavirus vaccines and risks of a “pandemic within a pandemic” with the emergence of  SARS-CoV-2 variants. Funding gaps at the ACT Accelerator and extending the shelf life of vaccines were also deliberated.

Research & Development Coronavirus COVID-19

Market Brief: Global Market For Arthroscopy And Sports Medicine Products Will Reach $6.3Bn By 2025

The global market for arthroscopy products and sports medicine implants is expected to reach $6.3bn by 2025, a CAGR of 1.9% from $5.7bn in 2020. The growth is driven partly by rising arthroscopy procedure volumes, expanding indications for joint repair, and patient preference for minimally invasive procedures. COVID-19 and downward pressures on device prices are among the growth barriers.  

Market Intelligence Orthopedics

Do It Yourself: Advantages Of Internal Gene Therapy Manufacturing

The number of gene therapies in development continues to rise, as trial sponsors widen the scope of addressable conditions, beyond ultra-rare diseases. Will manufacturing capacity – and payer budgets – be able to keep up?

Manufacturing Gene Therapy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Cortex Pharmaceuticals, Inc.
    • Pier Pharmaceuticals, Inc.
UsernamePublicRestriction

Register